Guangzhou Gloria Biosciences Co., Ltd.

4 in Phase 3

Quick facts

Phase 3 pipeline

Chemotherapy of Investigator's choice · Oncology
This is a phase 3 chemotherapy regimen selected by the investigator to treat cancer, with the specific mechanism dependent on the chosen chemotherapeutic agent(s).
GLS-010 · Diabetes
GLS-010 is a small molecule that targets the SGLT2 receptor.
Motixafortide+G-CSF · Oncology
Motixafortide is a CXCR4 antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood, used in combination with G-CSF (granulocyte-colony stimulating factor) to enhance stem cell mobilization for transplantation.
Placebo+G-CSF · Oncology
G-CSF stimulates the bone marrow to produce more neutrophils, a type of white blood cell.

Phase 1 pipeline

GLS-012

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Guangzhou Gloria Biosciences Co., Ltd.

What is Guangzhou Gloria Biosciences Co., Ltd.'s pipeline?

Guangzhou Gloria Biosciences Co., Ltd. has 4 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Chemotherapy of Investigator's choice, GLS-010, Motixafortide+G-CSF, Placebo+G-CSF.

Sector hub: All tracked pharma companies